Literature DB >> 29354770

Therapeutic drug monitoring in inflammatory bowel disease: too little too early?-comments on the American Gastroenterology Association Guideline.

Heidi Y Su1, Mark G Ward1, Miles P Sparrow1.   

Abstract

Entities:  

Year:  2017        PMID： 29354770      PMCID： PMC5763035          DOI： 10.21037/tgh.2017.12.05

Source DB:  PubMed          Journal:  Transl Gastroenterol Hepatol        ISSN： 2415-1289


× No keyword cloud information.
  24 in total

1.  TPMT Testing Before Starting Azathioprine or Mercaptopurine: Surely Just Do It?

Authors:  Jeremy D Sanderson
Journal:  Gastroenterology       Date:  2015-08-24       Impact factor: 22.682

Review 2.  American Gastroenterological Association Institute Guideline on Therapeutic Drug Monitoring in Inflammatory Bowel Disease.

Authors:  Joseph D Feuerstein; Geoffrey C Nguyen; Sonia S Kupfer; Yngve Falck-Ytter; Siddharth Singh
Journal:  Gastroenterology       Date:  2017-08-03       Impact factor: 22.682

3.  Undetectable anti-TNF drug levels in patients with long-term remission predict successful drug withdrawal.

Authors:  S Ben-Horin; Y Chowers; B Ungar; U Kopylov; R Loebstein; B Weiss; R Eliakim; E Del Tedesco; S Paul; X Roblin
Journal:  Aliment Pharmacol Ther       Date:  2015-06-01       Impact factor: 8.171

4.  Improved Long-term Outcomes of Patients With Inflammatory Bowel Disease Receiving Proactive Compared With Reactive Monitoring of Serum Concentrations of Infliximab.

Authors:  Konstantinos Papamichael; Karen A Chachu; Ravy K Vajravelu; Byron P Vaughn; Josephine Ni; Mark T Osterman; Adam S Cheifetz
Journal:  Clin Gastroenterol Hepatol       Date:  2017-03-30       Impact factor: 11.382

5.  Addition of an immunomodulator can reverse antibody formation and loss of response in patients treated with adalimumab.

Authors:  B Ungar; U Kopylov; T Engel; M Yavzori; E Fudim; O Picard; A Lang; N Williet; S Paul; Y Chowers; A Bar-Gil Shitrit; R Eliakim; S Ben-Horin; X Roblin
Journal:  Aliment Pharmacol Ther       Date:  2016-11-16       Impact factor: 8.171

6.  Combined Detection of NUDT15 Variants Could Highly Predict Thiopurine-induced Leukopenia in Chinese Patients with Inflammatory Bowel Disease: A Multicenter Analysis.

Authors:  Kang Chao; Xueding Wang; Qian Cao; Jiaming Qian; Kaichun Wu; Xia Zhu; Hong Yang; Jie Liang; Lang Lin; Zicheng Huang; Yu Zhang; Yibiao Huang; Yinghao Sun; Xianmin Xue; Min Huang; Pinjin Hu; Ping Lan; Xiang Gao
Journal:  Inflamm Bowel Dis       Date:  2017-09       Impact factor: 5.325

7.  Optimizing Anti-TNF-α Therapy: Serum Levels of Infliximab and Adalimumab Are Associated With Mucosal Healing in Patients With Inflammatory Bowel Diseases.

Authors:  Bella Ungar; Idan Levy; Yarden Yavne; Miri Yavzori; Orit Picard; Ella Fudim; Ronen Loebstein; Yehuda Chowers; Rami Eliakim; Uri Kopylov; Shomron Ben-Horin
Journal:  Clin Gastroenterol Hepatol       Date:  2015-10-29       Impact factor: 11.382

Review 8.  Review article: consensus statements on therapeutic drug monitoring of anti-tumour necrosis factor therapy in inflammatory bowel diseases.

Authors:  N Mitrev; N Vande Casteele; C H Seow; J M Andrews; S J Connor; G T Moore; M Barclay; J Begun; R Bryant; W Chan; C Corte; S Ghaly; D A Lemberg; V Kariyawasam; P Lewindon; J Martin; R Mountifield; G Radford-Smith; P Slobodian; M Sparrow; C Toong; D van Langenberg; M G Ward; R W Leong
Journal:  Aliment Pharmacol Ther       Date:  2017-10-13       Impact factor: 8.171

9.  Association of Induction Infliximab Levels With Clinical Response in Perianal Crohn's Disease.

Authors:  Yana Davidov; Bella Ungar; Haggai Bar-Yoseph; Dan Carter; Ola Haj-Natour; Miri Yavzori; Yehuda Chowers; Rami Eliakim; Shomron Ben-Horin; Uri Kopylov
Journal:  J Crohns Colitis       Date:  2017-05-01       Impact factor: 9.071

10.  Postinduction serum infliximab trough level and decrease of C-reactive protein level are associated with durable sustained response to infliximab: a retrospective analysis of the ACCENT I trial.

Authors:  Freddy Cornillie; Stephen B Hanauer; Robert H Diamond; Jianping Wang; Kezhen L Tang; Zhenhua Xu; Paul Rutgeerts; Séverine Vermeire
Journal:  Gut       Date:  2014-01-28       Impact factor: 23.059
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.